[CAS NO. 1380548-02-6] SR10067
PRODUCTS SPECIFICATIONS [1380548-02-6]
DESCRIPTION [1380548-02-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 465.58 |
| Molecular Formula | C31H31NO3 |
| SMILES | CC(OC1=CC=C(OCC2CC3=CC=CC=C3CN2C(C4=CC=CC5=C4C=CC=C5)=O)C=C1)(C)C |
Summary
IC50 & Target
IC50: 160 nM (Rev-Erbβ); 170 nM (Rev-Erbα) [1]
In Vitro
SR10067 has high affinity for Rev-Erbβ and Rev-Erbαwith IC 50 values are 160 and 170 nM, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SR10067 (i.p.; 30 mg/kg) has good pharmacokinetic properties in mouse [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Mice [1] |
| Dosage: | 30 mg/kg |
| Administration: | i.p. |
| Result: |
Remained above the IC
50
of the receptor in plasma and brain concentrations.
Suppressed the circadian rhythm of Npas2 gene expression in the mouse hypothalamus in a single injection and had a dose-dependent effect on reduction in nocturnal wheel running activity. Induced wakefulness and reduced SWS and REM sleep and displayed high anxiolytic activity. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 214.79 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1479 mL | 10.7393 mL | 21.4786 mL |
| 5 mM | 0.4296 mL | 2.1479 mL | 4.2957 mL |
| 10 mM | 0.2148 mL | 1.0739 mL | 2.1479 mL |
References
- [1] Banerjee S, et al. Pharmacological targeting of the mammalian clock regulates sleep architecture and emotional behaviour. Nat Commun. 2014 Dec 23;5:5759. doi: 10.1038/ncomms6759.
- [2] Thevis M, et al. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. Rapid Commun Mass Spectrom. 2016 Mar 15;30(5):635-51.